We studied the associations of macrophage activity, T-helper cell types 1 and 2 (Th-1/Th-2) responses, and iron status in 55 patients with hepatitis C virus (HCV)-related liver disease and 28 control patients with noninfectious liver disease. Serum concentrations of soluble tumor necrosis factor receptor type II (sTNFrec 75), a macrophage activation marker, were higher in cirrhotic than in noncirrhotic patients ( ) regardless of their HCV status, whereas P ! .001 levels of neopterin, interleukin (IL)-4 and IL-10 did not differ significantly. In HCV-positive patients, sTNFrec 75 levels and transferrin saturation (TfS) correlated positively with levels of aspartate transaminase ( for sTNFrec 75 and for TfS) and alanine trans-P ! .001 P = .028 aminase ( for sTNFrec 75 and for TfS). Increased TfS correlated significantly P = .003 P = .039 with both advanced liver disease and a predominant Th-2 pattern in HCV patients. Our data suggest that an association exists between macrophage activation and hepatic dysfunction, and that iron status may affect the clinical course of HCV infection by modulating Th-1/Th-2 responses in vivo.
rophages, as seen by reductions in major histocompatibility complex (MHC) class II expression, neopterin formation, and tumor necrosis factor (TNF)-a production; conversely, withdrawal of iron upon addition of the iron chelator desferrioxamine enhances these metabolic effects [11] . Therefore, ironloaded macrophages have a reduced cytotoxic potential toward various intracellular pathogens, including viruses [12] [13] [14] [15] .
Iron directs the immune response toward a Th-2 response pattern [16] [17] [18] , which is unfavorable for fighting a bacterial or viral infection. Moreover, intracellular iron availability modulates the expression of nitric oxide (NO) by regulating the transcription of nitric oxide synthase type II (NOS II, inducible NOS, iNOS) in macrophages [19] . NO formed by macrophages or hepatocytes in response to stimulation with IL-1, IFN-g, TNF-a, or lipopolysaccharide (LPS) [20, 21] plays a pivotal role in the body's defense against infectious agents, such as viruses [22] . Therefore, it seems possible that increased availability of iron in HCV patients may reduce the cytotoxic immune effector potential of the host against the viruses [23] . To test this hypothesis, we investigated the interactions among cellular immune effector function, iron availability, and clinical course in patients suffering from HCV infection.
Materials and Methods

Patients.
Eighty-three patients were included in the study. Fifty-five of these patients were HCV positive and 28 were HCV negative. Blood samples were taken as part of a routine examination. Patients investigated in this study had negative tests for autoimmune hepatitis, hepatitis B, Wilson's disease, a 1-antitrypsin deficiency, and a 1-fetoprotein; there was no ultrasonographic, computed tomographic, or liver biopsy-based evidence for hepa- tocellular carcinoma. Phenotypic hereditary hemochromatosis was excluded by performing genetic testing of patients who had either transferrin saturation (TfS) 145% or serum ferritin levels 1400 ng/ mL ( ). Patients are either homozygous or heterozygous for n = 17 1 of the known mutations of the HFE gene (C282Y, H63A), as checked by the polymerase chain reaction (PCR) method described elsewhere [24] , were excluded from the study ( ). Anti-HCV n = 5 was detected with a second-generation enzyme-linked immunosorbent assay and confirmed with nested PCR as described elsewhere [25] . Twenty-two of the HCV-infected patients investigated in this study had previously received anti-HCV treatment with IFN-a, but none of them had been receiving therapy for at least 6 months prior to their participation in this study. When we excluded those 22 patients who had previously received IFN-a, the statistical trends and results were almost the same as those described later for all patients (see Results). The diagnosis of cirrhosis was made on the basis of ultrasonographic and histopathologic examination after liver biopsy.
As controls, we recruited 28 patients who were examined at our outpatient clinic because of suspected chronic liver disease. All of these patients were negative for HCV and the laboratory tests listed earlier; 26 of these patients had fatty liver disease of various stages, and 2 had cryptogenic liver fibrosis. Ten of the 26 HCV-negative patients were given a diagnosis of nonalcoholic steatosis hepatis. In the control group, 17 (60.7%) of 28 patients regularly drank alcoholic beverages (112 g daily alcohol intake), whereas in the HCV group, 30 (54.5%) of 55 had a daily alcohol intake of 112 g.
Laboratory measurements. Serum specimens were drawn during a routine examination and stored at Ϫ70ЊC until cytokine assays were performed. Laboratory parameters, including alanine transaminase (ALT), aspartate transaminase (AST), hemoglobin, and iron content were determined by routinely used automated laboratory tests; ferritin concentration was determined by an immunoassay, and transferrin concentration by a turbidometric method. The sum of NO 2 Ϫ /NO 3 Ϫ was determined after reduction of nitrate with nitrate reductase with the Griess-Ilosvay's reagent as described elsewhere [26] . The level of neopterin was determined by means of a radioimmunoassay (Brahms, Berlin, Germany) with a detection limit of 2 nM. Determinations of serum concentrations of IL-4, IL-6, and IL-10 were all done by commercially available ELISA kits obtained from Genzyme (Cambridge, MA), Medgenix (Fleurus, Belgium), and Biosource International (Camarillo, CA), respectively. The detection limits were 2 ng/L for IL-4, 2 ng/L for IL-6, and 2 ng/L for IL-10. According to the manufacturers' information, normal serum values for neopterin are !10 nM: below the detection limit of the assay for IL-4, !10 ng/L for IL-6, and below the detection limit for IL-10.
Liver iron determination. Tissue iron concentrations were determined in a subgroup of 22 patients for whom liver biopsy specimens were still available; we used the method of Torrance and Bothwell [27] . Of these patients, 18 were HCV positive and 4 were HCV negative.
Statistical analysis. Analyses were done by use of the statistical software package SYSTAT 7.01 (SPSS, Chicago, IL). Continuous variables were compared according to HCV status, cirrhosis status, or transferrin saturation category by Student's t-test after Bonferroni correction for multiple tests. Proportions were compared by use of Fisher's exact test. Because these immunological parameters followed skewed rather than Gaussian distributions, they were also evaluated by nonparametric statistical analysis (Kruskal-Wallis) and a Bonferroni correction was applied when statistical significances were calculated. Logistic regression was used to examine the relationship of iron status and immunologic markers to cirrhosis after adjustment for age, previous therapy with IFN-a, baseline hemoglobin levels, leukocyte count, and serum creatinine concentrations. Correlations among various measures were assessed by use of Spearman ranks correlation technique.
Results
Iron and immune status in cirrhotic and noncirrhotic patients. In the subset of 22 patients tested, liver iron concentration was highly significantly correlated to both TfS ( ; ) and serum ferritin levels ( figure 1 ). This r = 0.599 P = .005 observation validates the use of the indirect measures of TfS and serum ferritin concentration to reflect iron status in this study. As shown in table 1, panel A, serum ferritin concentrations and transferrin saturations (TfSs) were significantly higher in cirrhotic than in noncirrhotic HCV-positive patients. No significant trends were found in markers of iron metabolism between noncirrhotic and cirrhotic HCV negative control patients (table 1, panel B). In logistic regression models involving HCV patients, serum ferritin and TfS levels were significantly associated with the finding of cirrhosis. Each 10 ng/mL increase in serum ferritin concentration was associated with a 1.1-fold increase in the odds of cirrhosis (95% confidence interval [CI], 1.02-1.2;
) after adjustment for age. Each 1% increase P = .02 in TfS was associated with an 1.3-fold increase in the likelihood of cirrhosis (95% CI, 1.04-1.6;
). P = .03 When we examined immune activation markers, we found sTNFrec 75 concentrations significantly higher in cirrhotic than in noncirrhotic patients in both the HCV-negative and HCVpositive groups (figure 2). The association between sTNFrec 75 and cirrhosis was confirmed by a logistic regression model: each 1000 ng/mL increase in sTNFrec 75 levels was associated with a 2.9-fold higher risk for the presence of cirrhosis (95% CI, 1.6-5.2; ) in HCV patients and with a 2.7-fold higher P ! .001 risk in non-HCV patients (95% CI, 1.6-4.5;
). sTNFrec P ! .001 75 had a stronger association with the finding of cirrhosis than did serum ferritin or TfS. Among measurements of liver enzyme we found significantly higher levels of AST and gGT when comparing cirrhotic with noncirrhotic HCV patients, whereas in HCV-negative patients, only gGT levels were significantly different (table 1) .
Iron and immune status in HCV-positive and HCV-negative patients. We next investigated possible differences according to stratification of patients by HCV infection. In noncirrhotic patients we found significantly higher levels of neopterin ( ), sTNFrec 75 ( ), and IL-10 ( ) in HCV-P = .01 P = .02 P = .05 positive as compared with HCV-negative individuals. Moreover, ALT activity ( ) was significantly elevated in HCV-P ! .001 positive, noncirrhotic patients as compared with HCV-negative, noncirrhotic patients ( ). There was a trend toward higher levels of AST in P = .07 patients with TfS 130%. Interestingly, these patients had significantly higher serum levels of the Th-2 cytokine IL-4 than patients with TfS !30%, whereas NO and neopterin concentrations tended to be lower when TfS was high (table 2). 
Interrelationship among liver damage, iron metabolism, and immune function.
To estimate the associations between the various parameters in our study, we next calculated Spearman rank correlations. As is evident from figure 3A , sTNFrec 75 concentrations significantly correlated with serum AST activity ( ), and they were also positively associated with ALT P ! .001 levels (
; data not shown). This was true in all patient P = .003 groups, but the trends were more pronounced in HCV-positive individuals. Similarly, we found a significant positive association between serum measures of iron status and liver cell enzyme activity with the closest correlations between AST and TfS ( , figure 3B), followed by ALT and serum iron P = .02 ( ), ALT and TfS ( ), AST and serum ferritin P = .02 P = .03 ( ), and ALT and serum ferritin ( ). P = .04 P = .09 On the basis of these data we next investigated a possible interrelationship between immune and iron markers in HCVpositive patients; our findings are shown in table 3. Interestingly, no significant interactions were found between TfS and sTNFrec 75. However, TfS was significantly related to IL-4 levels, and a negative correlation was observed between TfS and NO (table 3). Among immune activation markers the most striking significance was found between sTNFrec 75 and neopterin ( ); sTNFrec 75 also correlated significantly to P ! .001 macrophage-derived cytokines, such as IL-6 and IL-10, whereas neopterin was closely related to IL-10 and NO (table 3) .
Discussion
In this study we found a highly significant association between sTNFrec 75 levels and cirrhosis both in HCV-positive and HCV-negative individuals. Moreover, we identified correlations between iron status and more progressive liver disease in HCV patients, as well as interactions between iron parameters, liver damage, and immune effector function.
When comparing patients according to their HCV status and presence or absence of cirrhosis (table 1), we found that serum neopterin concentrations were significantly higher in HCV-positive compared with HCV-negative patients. Neopterin is produced and released in excess mainly by human macrophages in response to stimulation by IFN-g [29] . Therefore, neopterin is a clinically valuable marker for monitoring individuals with activated cellular immune response [30] . Other investigators have found that serum neopterin concentrations are useful in distinguishing patients with noninfectious liver disease from those with viral hepatitis [31, 32] , and, as mentioned earlier, our findings tend to confirm this observation. Histologic data are also supportive of this finding: an increased expression of Th-1 cytokines, such as IFN-g, is observed in liver biopsy specimens from patients with chronic HCV infection, compared with those from patients with noninfectious liver disease [33] .
In contrast to neopterin, sTNFrec 75 is not only produced in excess by macrophages upon stimulation with IFN-g, but can also be formed by challenging of macrophages with LPS, TNF-a, or IL-1, and presumably also by cell detritus products [34] . Therefore, sTNFrec 75 levels appear to be a reflection of an ongoing inflammatory response involving macrophages in the liver due to infectious and noninfectious agents. Because sTNFrec 75 levels were significantly different between cirrhotic and noncirrhotic patients, independent of the underlying cause of disease (figure 2), determination of sTNFrec levels may be a good surrogate marker to estimate both disease activity and progression to cirrhosis.
As with sTNFrec 75 levels, serum ferritin concentrations were increased in cirrhotic as compared with noncirrhotic patients (table 1) . In addition to reflecting high liver iron stores (figure 1), elevated serum ferritin concentrations may also indicate an ongoing inflammation and activity of liver disease, because ferritin expression is induced in hepatocytes upon stimulation with proinflammatory cytokines such as IL-1 or TNF-a [35] . The close correlation between serum ferritin concentration and hepatic iron concentration in a subset of 22 subjects (figure 1) confirms the validity of serum ferritin concentration as an indicator of iron status in the present study.
The close correlation between liver enzymes (AST and ALT) and sTNFrec 75 levels points to a possible relationship between macrophage activation and liver damage. This could either imply that stimulation of macrophages by an infectious agent or a toxic substance leads to destruction of liver cells via toxic radical formation by the immune cells, for example, or that just the opposite may be true. Apoptosis and destruction of hepatocytes after challenge with microorganisms or toxins might cause activation of Kupffer cells or invading monocytes by hepatocyte detritus products [36] .
Our finding that TfS levels are positively associated with with liver enzyme concentrations but not with sTNFrec 75 levels is consistent with the possibility that excessive iron may contribute to liver damage via its catalytic role for hydroxyl-radical formation. The close relationship between TfS and hepatic iron concentration in a subset of our patients supports this thesis. Nevertheless, increased serum iron levels and TfS in such patients might also be a reflection of iron release by damaged hepatocytes. In either case, our data are consistent with the possibility that excess iron then affects immune function. In macrophages, iron challenge causes an impaired response to stimulation by the Th-1 cytokine IFN-g [11] , thus reducing the cytotoxic effector potential of such macrophages towards various intracellular bacteria or viruses [12] [13] [14] [15] . Moreover, iron perturbations caused by various infections change the balance of Th-1/Th-2 cytokines by this basic mechanism. Although withdrawal of iron upon addition of an iron chelator, such as desferrioxamine, increases Th-1-mediated immune effector mechanisms including the formation of NO [16, 17] , Th-2 function appears to be weakened, as estimated by determination of anti-inflammatory cytokines such as IL-4 [16] [17] [18] . According to the Th-1/Th-2 paradigm by which Th-1 and Th-2 cytokines negatively affect each other's activity [2] , this observation could be due to macrophages' increased response to stimulation by IFN-g (Th-1) activity upon withdrawal of iron, which in turn leads to decreased Th-2 cell activity and Th-2 cytokine (e.g., IL-4) production.
Although a Th-1-mediated immune response appears to be necessary to gain control over acute viral infections, the damage to hepatocytes by a virus such as HCV may enhance the destruction of other cells by causing iron to be released, which subsequent increases the formation of radicals [36] . At the same time, increased iron concentrations may also weaken the immune potential of macrophages against viruses by directing the immune response from a Th-1 to a Th-2 pattern [3, 4] . This is suggested by our data that show both a significant positive correlation between TfS and IL-4 (Th-2) levels and a negative trend between TfS and macrophage activation markers such as NO (Th-1, table 3 ). This last observation might also be due to a negative regulatory effect of iron on NOS II transcription, as has been shown in murine macrophages [19] . These mechanisms could then account for impaired killing of viruses by macrophages upon iron perturbations, [15] because NO is centrally involved in the body's defense mechanism toward viral infections [22] and may also be a key factor for the host response toward HCV infection [37, 38] .
The impact of iron homeostasis on the immune response in HCV infection has also been emphasized by data showing that the clinical response to IFN-a is reduced in patients with in-creased hepatic iron stores [4] [5] [6] [7] [8] . This could possibly be due to an inhibitory effect of iron on IFN-a action, in a fashion comparable to that shown for IFN-g [10] , because type I and type II interferons share similar signal transduction mechanisms in cells [39] . The trend evident in our study, toward a higher prevalence of cirrhosis in patients with high TfS (table 3) , could be a reflection of the mechanism described earlier by which iron directs the immune response to a Th-2 pattern (IL-4; table 3). In turn, the Th-2 pathway downregulates the antiviral effector mechanisms of macrophages and Kupffer cells, while at the same time causes hepatocyte damage by catalyzing radical formation [36, 40] . Patients with higher TfS might also respond poorly to IFN-a because of a dominant Th-2 response that may inhibit some of the pathways induced by type I interferons toward target cells [2] [3] [4] .
It is tempting to speculate about whether patients could benefit from iron reduction therapy. Iron chelation could increase the Th-1-mediated immune response and antimicrobial effector mechanism of macrophages. Such an effect has been shown in P. falciparum infection [16, 18] , in which iron chelation contributes to more efficient clearance of parasites [41] . Such an effect has also been suggested for viral infections by a recent phlebotomy study [42] . Alternatively, iron chelation may reduce liver damage via withdrawal of iron, thus preventing toxic hydroxyl-radical formation by the catalytic action of the metal [43] .
It will be interesting in future studies to investigate (1) the impact of iron metabolism on cellular immune function, response to cytokine therapy, and progression of disease in patients with HCV infection in longitudinal investigations; (2) the definitive mechanism and background for the association between macrophage activation and liver damage; (3) the cutoff value of sTNFrec 75 levels to estimate the risk of cirrhosis and the activity of a liver disease; and (4) the value of neopterin to distinguish between infectious (HCV) and noninfectious liver disease.
